ANI Pharmaceuticals, Inc. (ANIP) Shares Sold by Raymond James & Associates

Raymond James & Associates reduced its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 6.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 21,462 shares of the specialty pharmaceutical company’s stock after selling 1,528 shares during the period. Raymond James & Associates owned approximately 0.18% of ANI Pharmaceuticals worth $1,383,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ANIP. Cortina Asset Management LLC purchased a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $6,091,000. JPMorgan Chase & Co. raised its holdings in ANI Pharmaceuticals by 868.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 104,829 shares of the specialty pharmaceutical company’s stock valued at $5,404,000 after buying an additional 94,002 shares during the period. Dimensional Fund Advisors LP raised its holdings in ANI Pharmaceuticals by 25.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 424,797 shares of the specialty pharmaceutical company’s stock valued at $22,297,000 after buying an additional 85,529 shares during the period. Triarii Capital Management LP purchased a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $3,283,000. Finally, Algert Global LLC acquired a new position in ANI Pharmaceuticals in the 4th quarter valued at about $1,966,000. Hedge funds and other institutional investors own 55.77% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other news, Director Tracy Marshbanks sold 15,391 shares of the business’s stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $63.08, for a total transaction of $970,864.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel Raynor sold 27,964 shares of the business’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $62.24, for a total value of $1,740,479.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 187,620 shares of company stock valued at $11,696,748. 33.10% of the stock is currently owned by corporate insiders.

Several research firms have weighed in on ANIP. BidaskClub downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 24th. ValuEngine downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 2nd. TheStreet downgraded ANI Pharmaceuticals from a “b” rating to a “c+” rating in a research report on Tuesday, February 20th. Zacks Investment Research downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, Canaccord Genuity set a $77.00 target price on ANI Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, December 29th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $72.25.

NASDAQ ANIP opened at $61.14 on Wednesday. The stock has a market capitalization of $698.04, a price-to-earnings ratio of 16.94 and a beta of 2.90. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.36 and a quick ratio of 2.39. ANI Pharmaceuticals, Inc. has a 1-year low of $42.23 and a 1-year high of $74.70.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.06. The company had revenue of $47.30 million during the quarter, compared to the consensus estimate of $52.55 million. ANI Pharmaceuticals had a positive return on equity of 23.41% and a negative net margin of 0.61%. ANI Pharmaceuticals’s revenue was up 23.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.84 EPS. sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 5.17 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “ANI Pharmaceuticals, Inc. (ANIP) Shares Sold by Raymond James & Associates” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.thelincolnianonline.com/2018/04/18/ani-pharmaceuticals-inc-anip-shares-sold-by-raymond-james-associates.html.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply